A Reliable Indirect ELISA Protocol for Detection of Human Antibodies Directed to SARS-CoV-2 NP Protein

Arwa A. Faizo,Thamir A. Alandijany,Ayman T. Abbas,Sayed S. Sohrab,Sherif A. El-Kafrawy,Ahmed M. Tolah,Ahmed M. Hassan,Esam I. Azhar
DOI: https://doi.org/10.3390/diagnostics11050825
IF: 3.6
2021-05-02
Diagnostics
Abstract:A few months ago, the availability of a reliable and cost-effective testing capacity for COVID-19 was a concern for many countries. With the emergence and circulation of new SARS-CoV-2 variants, another layer of challenge can be added for COVID-19 testing at both molecular and serological levels. This is particularly important for the available tests principally designed to target the S gene/protein where multiple mutations have been reported. Herein, the SARS-CoV-2 NP recombinant protein was utilized to develop a simple and reliable COVID-19 NP human IgG ELISA. The optimized protocol was validated against a micro-neutralization (MN) assay, in-house S-based ELISA, and commercial chemiluminescence immunoassay (CLIA). The developed assay provides 100% sensitivity, 98.9% specificity, 98.9% agreement, and high overall accuracy with an area under curve equal to 0.9998 ± 0.0002 with a 95% confidence interval of 0.99 to 1.00. The optical density values of positive samples significantly correlated with their corresponding MN titers. The assay specifically detects IgG antibodies to the SARS-CoV-2 NP protein and does not cross-detect IgG to the viral S protein. Moreover, it does not cross-react with antibodies related to other coronaviruses (e.g., the Middle East respiratory syndrome coronavirus or human coronavirus HKU1). The availability of this reliable COVID-19 NP IgG ELISA protocol is highly valuable for its diagnostic and epidemiological applications.
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to develop a reliable and cost - effective indirect ELISA (enzyme - linked immunosorbent assay) protocol for detecting human antibodies against the SARS - CoV - 2 nucleocapsid (NP) protein. Specifically, the researchers focus on the following aspects: 1. **Improving detection accuracy**: With the emergence of new SARS - CoV - 2 variants, existing detection methods mainly targeting the S gene/protein may be affected by new mutations. Therefore, developing an ELISA method targeting the NP protein can provide more stable detection results. 2. **Validating the effectiveness of the new method**: The researchers verified the sensitivity, specificity, consistency and overall accuracy of the newly developed NP IgG ELISA method by comparing it with the microneutralization (MN) test, a self - established ELISA based on the S protein, and a commercial chemiluminescence immunoassay (CLIA). 3. **Evaluating cross - reactivity**: The researchers evaluated whether the new method would cross - react with antibodies related to the S protein of SARS - CoV - 2 or other coronaviruses (such as Middle East respiratory syndrome coronavirus MERS - CoV and human coronavirus HKU1). 4. **Distinguishing natural infection from vaccination**: As more and more people are vaccinated against COVID - 19, it becomes particularly important to distinguish immunity resulting from natural infection from that resulting from vaccination. The researchers showed that the NP - based ELISA method can effectively distinguish between the two. In summary, the main objective of this paper is to provide a new, reliable SARS - CoV - 2 NP IgG ELISA detection method to address the possible challenges faced by existing detection methods and play an important role in diagnosis and epidemiological research.